Bank of New York Mellon Corp Acquires 5,213 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Bank of New York Mellon Corp boosted its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 2.5% in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 210,599 shares of the medical instruments supplier’s stock after buying an additional 5,213 shares during the quarter. Bank of New York Mellon Corp owned 0.94% of LeMaitre Vascular worth $17,328,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of LMAT. West Oak Capital LLC bought a new stake in shares of LeMaitre Vascular in the second quarter worth approximately $58,000. Louisiana State Employees Retirement System grew its position in LeMaitre Vascular by 3.1% in the 2nd quarter. Louisiana State Employees Retirement System now owns 10,100 shares of the medical instruments supplier’s stock worth $831,000 after purchasing an additional 300 shares during the period. Fifth Third Bancorp raised its stake in LeMaitre Vascular by 6.6% during the 2nd quarter. Fifth Third Bancorp now owns 10,888 shares of the medical instruments supplier’s stock valued at $896,000 after buying an additional 678 shares during the last quarter. Hennion & Walsh Asset Management Inc. lifted its holdings in shares of LeMaitre Vascular by 62.2% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 10,289 shares of the medical instruments supplier’s stock valued at $847,000 after buying an additional 3,947 shares during the period. Finally, Sequoia Financial Advisors LLC bought a new position in shares of LeMaitre Vascular during the 2nd quarter valued at $1,010,000. Hedge funds and other institutional investors own 84.64% of the company’s stock.

Analyst Upgrades and Downgrades

LMAT has been the topic of a number of recent research reports. JMP Securities increased their target price on LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a report on Tuesday, August 20th. Barrington Research increased their price objective on shares of LeMaitre Vascular from $79.00 to $92.00 and gave the stock an “outperform” rating in a research note on Friday, August 2nd. Roth Mkm restated a “buy” rating and set a $100.00 target price on shares of LeMaitre Vascular in a research report on Friday, May 31st. Lake Street Capital began coverage on shares of LeMaitre Vascular in a research report on Friday, August 2nd. They issued a “buy” rating and a $105.00 price target on the stock. Finally, Roth Capital raised shares of LeMaitre Vascular to a “strong-buy” rating in a research report on Friday, May 31st. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $94.40.

Insider Buying and Selling

In other LeMaitre Vascular news, Director David B. Roberts sold 3,063 shares of the firm’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $82.07, for a total transaction of $251,380.41. Following the completion of the transaction, the director now owns 14,114 shares in the company, valued at approximately $1,158,335.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, CEO George W. Lemaitre sold 27,030 shares of the firm’s stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $86.27, for a total value of $2,331,878.10. Following the completion of the sale, the chief executive officer now directly owns 1,958,328 shares of the company’s stock, valued at approximately $168,944,956.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director David B. Roberts sold 3,063 shares of LeMaitre Vascular stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $82.07, for a total value of $251,380.41. Following the completion of the transaction, the director now owns 14,114 shares of the company’s stock, valued at approximately $1,158,335.98. The disclosure for this sale can be found here. Over the last three months, insiders have sold 43,251 shares of company stock worth $3,714,994. Corporate insiders own 10.79% of the company’s stock.

LeMaitre Vascular Price Performance

Shares of LMAT stock opened at $88.06 on Friday. LeMaitre Vascular, Inc. has a one year low of $44.27 and a one year high of $92.90. The company’s fifty day moving average price is $85.59 and its 200-day moving average price is $76.17. The company has a market capitalization of $1.98 billion, a price-to-earnings ratio of 58.19, a PEG ratio of 2.38 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of $0.47 by $0.05. LeMaitre Vascular had a return on equity of 12.41% and a net margin of 18.33%. The business had revenue of $55.85 million for the quarter, compared to analysts’ expectations of $54.98 million. During the same period last year, the firm earned $0.37 earnings per share. The business’s quarterly revenue was up 11.4% on a year-over-year basis. Equities research analysts expect that LeMaitre Vascular, Inc. will post 1.85 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, August 29th. Stockholders of record on Thursday, August 15th were issued a $0.16 dividend. The ex-dividend date was Thursday, August 15th. This represents a $0.64 annualized dividend and a dividend yield of 0.73%. LeMaitre Vascular’s dividend payout ratio (DPR) is 42.38%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.